Previous close | 3.9000 |
Open | 3.8500 |
Bid | 4.0500 x 300 |
Ask | 4.1300 x 300 |
Day's range | 3.6706 - 4.3250 |
52-week range | 1.6300 - 8.8300 |
Volume | |
Avg. volume | 2,659,977 |
Market cap | 464.373M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.6400 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.80 |
Despite Revenue Growth, Losses Widen; Clinical Trials Progress in Autoimmune and Cancer Treatments
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 0% and 140.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease Enrollment Initiated with FT522 CAR NK Cell Product Candidate in Conditioning-free Treatment Arm of Phase 1 B Cell Lymphoma Study First Patient Treated with FT825 / ONO-8250 CAR T-cell Product Candidate in Phase 1 Solid Tumor Study $391 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, May 09, 2024 (GLOBE NE